A retrospective comparison of clarithromycin versus rifampin in combination treatment for disseminated Mycobacterium avium complex disease in AIDS: Clarithromycin decreases transfusion requirements

International Journal of Tuberculosis and Lung Disease

Volumn 1, Issue 2, 1997, Pages 163-169

  Burman, W J ^a,c   Reves, R R ^a,b   Rietmeijer, C A ^a,b   Cohn, D L ^a,b  

^a Denver Disease Control Service   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NONE   (United States)

Author keywords

AIDS; Clarithromycin; Mycobacterium avium complex; Rifampin; Transfusion

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; AIDS RELATED COMPLEX; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTEREMIA; BLOOD TRANSFUSION; COMPARATIVE STUDY; DRUG COMBINATION; EVALUATION; FEMALE; HEALTH CENTER; HUMAN; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; STATISTICS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; BACTEREMIA; BLOOD TRANSFUSION; CLARITHROMYCIN; COLORADO; COMMUNITY HEALTH CENTERS; DRUG THERAPY, COMBINATION; EVALUATION STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETROSPECTIVE STUDIES; RIFAMPIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031107945     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Katz M H, Hessol N A, Buchbinder S P, Hirozawa A, O'Malley P, Holmberg S D. Temporal trends of opportunistic infections and malignancies in homosexual men with AIDS. J Infect Dis 1994; 170: 198-202.
2. Kerlikowske K M, Katz M H, Chan A K, Perez-Stable E J. Antimycobacterial therapy for disseminated Mycobacterium avium complex infection in patients with acquired immunodeficiency syndrome. Arch Intern Med 1992; 152: 81.3-817.
3. Chin D P, Reingold A L, Stone E N, et al. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - a prospective study. J Infect Dis 1994; 170: 578-584.
4. Horsburgh C R Jr, Metchock B, Gordon S M, Havlik J A Jr, McGowan J E Jr, Thompson S E III. Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease. J Infect Dis 1994; 170: 573-577.
5. Fernandes P B, Hardy D J, McDaniel D, Hanson C W, Swanson R N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium Antimicrob Agents Chemother 1989; 33: 1531-1534.
6. Dautzenberg B, Truffot C, Legns S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: a controlled trial. Am Rev Respir Dis 1991; 144: 564-569.
7. Chaisson R E, Benson C A, Dube M P, et al. Clanthromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905-911.
8. Kemper C A, Meng T C, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a fourdrug regimen: rifampin, ethambutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992; 116: 466-472.
9. Chui J, Nussbaum J, Bozette S, et al Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med 1990; 113: 358-361.
10. Public Health Service task force on prophylaxis and therapy for Mycobacterium avium complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993; 329: 898-904.
11. Goldberger M, Masur H. Clarithromycin therapy for Mycobacterium avium complex disease in patients with AIDS: potential and problems. Ann Intern Med 1994; 121: 974-976.
12. Sommers H M, Good R C. Mycobacterium. In: Lennette E H, Balows A, Hausler W J Jr, Shodomy J H, eds. Manual of Clinical Microbiology. 4th ed. Washington, DC: American Society for Microbiology 1985; 216-248.
13. Heifets L B, Lindholm-Levy P J, Comstock R D. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992; 145: 856-858.
14. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morb Mortal Wkly Rep 1987; 36 (supplement): 1-36.
15. Chaisson R E, Schecter G F, Theuer C P, Rutherford G W, Echenberg D F, Hopewell P C. Tuberculosis in patients with the acquired immunodeficiency syndrome: clinical features, response to therapy, and survival. Am Rev Respir Dis 1987; 136: 570-574.
16. Sathe S S, Gascone P, Lo W, Pinto R, Reichman L B. Severe anemia is an important negative predictor for survival with disseminated Mycobacterium avium-intracellulare in acquired immunodeficiency syndrome. Am Rev Respir Dis 1990; 142: 1306-1312.
17. Havlik J A Jr, Horsburgh C R Jr, Metchock B, Williams P P, Fann S A, Thompson S E III. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992; 165: 577-580.
18. Jacobson M A, Peiperl L, Volberding P A, Porteus D, Toy P T C Y, Feigal D. Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome. Transfusion 1990; 30: 133-137.
19. Ives D V, Davis R B, Currier J S. Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobaeterium avium complex. AIDS 1995; 9: 261-266.
20. Shafran S D, Singer J, Zarowny D P, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996; 335: 377-383.